Methods are needed to reliably prioritize biologically active driver mutations over inactive passengers in highthroughput sequencing cancer data sets. We present ParsSNP, an unsupervised functional impact predictor that is guided by parsimony. ParsSNP uses an expectation-maximization framework to find mutations that explain tumor incidence broadly, without using predefined training labels that can introduce biases. We compare ParsSNP to five existing tools (CanDrA, CHASM, FATHMM Cancer, TransFIC, and Condel) across five distinct benchmarks. ParsSNP outperformed the existing tools in 24 of 25 comparisons. To investigate the realworld benefit of these improvements, we applied ParsSNP to an independent data set of 30 patients with diffuse-type gastric cancer. ParsSNP identified many known and likely driver mutations that other methods did not detect, including truncation mutations in known tumor suppressors and the recurrent driver substitution RHOA p.Tyr42Cys. In conclusion, ParsSNP uses an innovative, parsimony-based approach to prioritize cancer driver mutations and provides dramatic improvements over existing methods.
Methods are needed to reliably prioritize biologically active driver mutations over inactive passengers in highthroughput sequencing cancer data sets. We present ParsSNP, an unsupervised functional impact predictor that is guided by parsimony. ParsSNP uses an expectation-maximization framework to find mutations that explain tumor incidence broadly, without using predefined training labels that can introduce biases. We compare ParsSNP to five existing tools (CanDrA, CHASM, FATHMM Cancer, TransFIC, and Condel) across five distinct benchmarks. ParsSNP outperformed the existing tools in 24 of 25 comparisons. To investigate the realworld benefit of these improvements, we applied ParsSNP to an independent data set of 30 patients with diffuse-type gastric cancer. ParsSNP identified many known and likely driver mutations that other methods did not detect, including truncation mutations in known tumor suppressors and the recurrent driver substitution RHOA p.Tyr42Cys. In conclusion, ParsSNP uses an innovative, parsimony-based approach to prioritize cancer driver mutations and provides dramatic improvements over existing methods.
As genome sequencing becomes less expensive, there is a pressing need for functional impact scores that can computationally prioritize pathogenic mutations for experimental or therapeutic follow-up. The need is especially acute in cancer genomics. Sequencing of paired tumor-normal samples has identified millions of protein-altering somatic mutations in thousands of patients 1 , but functional characterization and clinical decision-making are stymied by neutral 'passenger' mutations that greatly outnumber pathogenic 'driver' mutations 2 .
Many newer functional impact scores predict pathogenic variants using supervised modeling [3] [4] [5] . A model is trained using mutations that are designated as pathogenic or neutral. An advantage of this strategy is that models can be developed for specific tasks by choosing appropriate training data. For instance, curated training data allow CanDrA and CHASM to detect cancer drivers specifically 6, 7 . However, training data also introduce biases that can skew models toward known biology and limit generalizability 8 . Previously, diverse sources including HGMD, dbSNP, UniProt, COSMIC, and simulated mutations have provided training examples, each requiring assumptions as to what constitutes a pathogenic or neutral mutation [3] [4] [5] [6] [7] . In general, supervised modeling may not be tractable if available data sets do not adequately represent the sought-after classes of mutations.
We present a new unsupervised method for identifying driver mutations that is guided by parsimony rather than predetermined training labels. This approach assumes that drivers are more equitably distributed among samples than passengers or, equivalently, that the proportion of mutations that are drivers drops as tumor mutation rates increase. This assertion follows from previous observations; studies by ourselves and Youn et al. demonstrate that cancer-related genes (which are enriched in driver mutations) are mutated in relatively hypomutated tumors more often than expected by chance 9, 10 . More recently, Tomasetti et al. showed that cancers depend on a small but consistent number of driver events, over all mutation rates 11 .
Our goal is to use this knowledge to train a parsimonious model that predicts a few drivers in each patient. We adapt an expectationmaximization framework to identify a PARsimonius Set of Simple Nucleotide Polymorphisms that broadly explains cancer incidence in a training set of unlabeled pan-cancer mutations (ParsSNP). We then train a model to identify these putative drivers and detect similar mutations prospectively. This approach should be more generalizable than existing methods because it uses relatively simple assumptions and avoids the need for prelabeled training data. Additionally, unlike most previous methods, our approach is applicable to all single-nucleotide substitutions (including synonymous, nonsynonymous, and premature stop mutations) and small frameshift and in-frame indels.
We first characterize the process of training ParsSNP. We then use five classification tasks to assess the ability of ParsSNP and other independent tools to detect likely or known driver mutations in pancancer and other data sets. We also compare the predictions that these tools produce in an independent cancer exome sequencing data set, representing a typical usage scenario. Finally, we discuss specific driver mutations and genes proposed by ParsSNP.
RESULTS

ParsSNP overview
ParsSNP identifies likely drivers using a training set of unlabeled mutations from a collection of biological samples and two constraints. First, predicted drivers should be few in number and distributed relatively Unsupervised detection of cancer driver mutations with parsimony-guided learning equitably among samples. Second, predicted drivers must be identifiable using known, quantifiable qualities of the mutations (descriptors). Figure 1a provides an overview of ParsSNP, with details in the Online Methods. There is a learning and application phase.
In the learning phase, ParsSNP generates probabilistic driver labels for the training mutations. The labels are initialized with random values from 0 to 1; they are then iteratively refined by expectationmaximization, with each step representing a constraint. In the expectation step, each label is updated using Bayes' law and the assumption that, in a sample with n mutations, between 1 and log 2 (n) mutations drive tumor growth. Because this range scales logarithmically, the expectation step ensures that predicted drivers are uncommon and relatively equitably distributed among samples. The maximization step builds a probabilistic model and updates the labels using the descriptors in cross-validation, ensuring that predicted drivers can always be defined in terms of the descriptors. We use a neural network, as this model produces well-scaled probabilities 12 . The expectation step and maximization step iterate until convergence.
In the application phase, the refined labels are used to train a final ParsSNP neural network. For clarity, we differentiate between the probabilistic 'ParsSNP labels' produced by expectation-maximization for the training data and the 'ParsSNP scores' , which are defined by the model in all data sets (Fig. 1a) .
Data sets and analysis
Our pan-cancer data set had 1,703,709 protein-altering somatic mutations from 10,239 samples 9 , broken into three partitions: a 435-sample (851,996-mutation) 'hypermutator' set; a 6,536-sample (566,223-mutation) 'training' set; and a 3,268-sample (285,490-mutation) 'test' set. We also used experimental and germline data. The 'driver-dbSNP' data set had 49,880 common variants from dbSNP plus 1,138 experimentally validated drivers from Kin-Driver 13 and Martelotto et al. 14 ; the 'p53' data set had 2,314 mutations from the International Agency for Research on Cancer (IARC) R17 p53 systematic yeast screen 15 17 . We also made use of the Cancer Gene Census (CGC), excluding genes that are only involved in translocations 18, 19 . We used 23 descriptors, including 16 published functional impact scores together with 3 mutation-level and 4 genelevel annotations (further details in the Online Methods).
Because no 'gold standard' for cancer drivers exists, we used the above data sets to assess ParsSNP in five proxy classification tasks ( Table 1) : (i) detection of recurrent mutations in the pan-cancer test set (which occur in two or more samples) as important driver proxies 6 ; (ii) detection of pan-cancer test set mutations within CGC members, as mutations in cancer-related genes are more likely to be drivers (the scope is limited to non-recurrent test set mutations so as to avoid redundancy with the previous task); (iii) detection of experimentally defined drivers among presumably neutral common germline variants (the driver-dbSNP data set resembles real-world data in that mutations are drawn from many genes and drivers are rare); (iv) detection t e c h n i c a l r e p o r t s of disruptive events (mutant activity <25% of wild-type activity) in the p53 systematic yeast screen; and (v) separation of mutations in the functional-neutral data set 16 . Although small, the functional-neutral data set has two unique features: first, functional and neutral variants are validated experimentally and, second, the data set is curated, with a small number of functional and neutral variants in each of several well-known cancer-related genes. Note that the training of ParsSNP and control methods does not change from task to task, and all methods are trained and tested on the same data sets. Our primary performance measure was area under the receiver operator characteristic (AUROC). AUROCs summarize performance across all prediction thresholds and are statistically testable, and they were used for these reasons previously 7 . These values are equivalent to the accuracy of a tool when sorting random pairs consisting of one driver and one passenger (the corresponding error rate of the tool is equal to 1 -AUROC). They can range from 0.5 (random classification) to 1.0 (perfect classification; discussed further in the Online Methods).
For each task, we compared ParsSNP scores to competing functional impact scores that detect cancer drivers but were not used as descriptors. These 'independent tools' included CanDrA, a supervised ensemble method trained to detect recurrent mutations in pancancer data 6 ; CHASM, a supervised model trained using curated cancer mutations 7 ; FATHMM Cancer, a hidden Markov model (HMM)-based approach 20 ; TransFIC, a method of recalibrating functional npg t e c h n i c a l r e p o r t s impact scores for cancer data (the base score is MutationAssessor, which had the best performance in the original study) 21 ; and Condel, an ensemble method that was not designed specifically for cancer but was shown by its authors to be useful for detecting drivers 22 . Each tool was applied using published software (see URLs). Matching or improving upon the performance of these tools will demonstrate the value of ParsSNP.
ParsSNP training
An expectation-maximization approach requires careful empirical testing to ensure that it returns an appropriate result. ParsSNP consistently converged within 15-20 iterations (Supplementary Fig. 1a ). It was highly reproducible, with an average pairwise correlation of 0.99 over 50 runs. Although small, the variations led us to average the 50 runs for the final labels. ParSNP labels are right-skewed, as expected, suggesting that a minority of mutations are drivers (Fig. 1b) . After training the final ParsSNP model using these labels, we assessed the contribution of descriptors to the neural network using Garson's algorithm (as described by Olden et al. 23 ; Fig. 1c) . We found that all descriptors made at least moderate contributions to the model. ParsSNP is trained such that putative driver mutations should be distributed relatively equitably among samples (enriched in the least mutated samples and depleted in hypermutators on a per-mutation basis). We assessed whether ParsSNP scored mutations in this way (Fig. 1d) . Mutations from less mutated tumors were more likely to be identified as drivers regardless of ParsSNP threshold; this pattern extended into the hypermutator set, which was not used for training. On average, hypermutators had 23 times more mutations than nonhypermutators (1,958 versus 86.6) but only 5.5 times more mutations with ParsSNP scores over 0.1 (7.17 versus 1.3). At a very stringent ParsSNP score cutoff of 0.5, the ratio was only 3.3 (0.23 versus 0.07). Therefore, ParsSNP assigns putative drivers relatively evenly in both the training and held-out hypermutator sets, suggesting that the parsimony-guided training worked as intended.
Both the training data and several tunable parameters may affect algorithm behavior. To test consistency across data sets, we split the training data into two equal halves and found that ParsSNP produced highly correlated scores (r = 0.96; Supplementary Fig. 1b) . We also compared the results from 15 alternative parameter settings to the labels produced with the default settings (reference) ( Supplementary  Fig. 2 and Supplementary Table 2 ). The algorithm consistently converged and usually produced labels that were highly correlated with the reference. We also ran a variety of methodological controls, including simplified and supervised versions of ParsSNP and genelevel driver detection tools. These controls indicated that ParsSNP's performance largely derives from its parsimony-based training and descriptor set (particularly the use of gene-level data). This analysis is portrayed in Supplementary Figs. Table  3 and is discussed in depth in the Online Methods.
3-7 and Supplementary
Testing ParsSNP with pan-cancer data
We applied ParsSNP to the withheld test data set of 3,268 pan-cancer tumors (285,490 mutations). Because the independent tools do not apply to synonymous and truncating mutations, we limited the analysis to 182,483 missense mutations, except where noted.
The first classification task was to identify recurrent mutations, as these are often treated as drivers 6 . ParsSNP scores were positively correlated with mutation recurrence (Fig. 2a) and were more highly associated with recurrence than scores from any of the independent tools (Fig. 2b) . Overall, ParsSNP identified 9,434 recurrent missense mutations with AUROC = 0.656 (95% confidence interval (CI) = 0.650-0.663), better than any independent tool (all Delong P < 2.2 × 10 −16 ; Fig. 2c and Table 1 npg t e c h n i c a l r e p o r t s considering that it was trained with recurrent mutations 6 . Recurrence also provides an opportunity to assess ParsSNP performance within genes, which is crucial because ParsSNP uses gene-level descriptors and 75% of its variation is between genes (based on sums of squares). ParsSNP generally performed as well in single genes as it did in the entire data set (Fig. 2d) . The second classification task was to identify mutations in one of 208 CGC members, which should be enriched in driver events. We limited the scope to non-recurrent missense mutations to avoid confounding with the previous analysis. ParsSNP identified 3,760 non-recurrent mutations in cancer-related genes with AUROC = 0.833 (95% CI = 0.825-0.841), with better performance than the independent tools (all Delong P < 2.2 × 10 −16 ; Fig. 2e and Table 1) .
Unlike the independent tools, ParsSNP applies to mutations besides missense events (Online Methods). It is biologically intuitive that there will be an interaction between mutation type and gene type in predicting drivers: we expect that truncations (frameshifts and premature stops) are less likely to be drivers than missense mutations when present in oncogenes, whereas the opposite is true in tumorsuppressor genes (TSGs), and silent mutations are unlikely to be drivers regardless of gene type 2 . We split CGC members into putative oncogenes and TSGs (Online Methods) and found that ParsSNP was able to identify this pattern (Fig. 2f) . We questioned which descriptors were responsible for this ability, as ParsSNP is not directly aware of gene type. 'Truncation rate' , which separates oncogenes and TSGs on the basis of rates of truncation events 9 , showed a marked interaction with mutation type (Supplementary Fig. 8a ). The ability to detect interactions between descriptors illustrates the value of using a neural network rather than a simpler model (Supplementary Fig. 8b ).
Testing ParsSNP with experimental data In our third classification task, we assessed ParsSNP's performance in the driver-dbSNP data set, which combines a large number of (presumably neutral) common germline variants with relatively few experimentally validated drivers. In this data set, 13,738 genes are mutated at least once and 49 have at least one functional mutation. ParsSNP detected the drivers with AUROC = 0.975 (95% CI = 0.970-0.981; Fig. 3a) , slightly better than FATHMM Cancer (Delong P = 0.205; Table 1 ) and significantly better than the other independent tools (all Delong P < 1 × 10 −4 ).
The fourth classification task focused on the IARC p53 data set, which consists of p53 transactivation activity against downstream targets for 2,314 missense mutations 15 . As with many functional impact scores, ParsSNP scores were higher for mutations that abrogate p53 activity (Fig. 3b) . However, ParsSNP scores were more strongly associated with the fold change in p53 activity than any of the independent tools (Fig. 3c) . ParsSNP was a strong performer when identifying the 475 mutations that reduce p53 activity to 25% or less of wild-type activity. It outperformed CanDrA, FATHMM Cancer, and TransFIC (all Delong P < 0.05), although it was statistically tied with CHASM (Delong P = 0.39) and Condel (Delong P = 0.59; Fig. 3d and Table 1 ).
The final classification task used the functional-neutral data set of 71 experimentally validated functional and neutral mutations. ParsSNP markedly outperformed existing methods in this task (AUROC = 0.834, 95% CI = 0.735-0.933; Fig. 3e and Table 1 ). The result was significant in the cases of CanDrA, FATHMM Cancer, Condel, and TransFIC (all Delong P < 0.05) and trending in the case of CHASM, likely because of the limited size of the data set (CHASM AUROC = 0.695, Delong P = 0.085).
ParsSNP performance summary
As Table 1 shows, ParsSNP outperformed the independent tools in 24 of 25 comparisons. Moreover, as a summary of accuracy, modest differences in AUROCs can imply large performance gains under particular conditions. For instance, several tools perform the driverdbSNP task well, often with AUROCs over 0.90. However, because AUROCs of 1.0 represent perfect accuracy, small improvements represent large drops in the AUROC error rate. For example, ParsSNP's performance in this task (AUROC = 0.975) represents more than a twofold reduction in errors when compared to CHASM (AUROC = 0.948). Another valuable consideration is the precision (positive predictive value) if only a few predictions can be tested. ParsSNP and CanDrA had the top overall performance in the recurrence task (AUROC = 0.656 and 0.608, respectively). However, when considering only the top 100 hypotheses from each tool, ParsSNP had a precision of 98% (2 false positives), whereas CanDrA had a precision of only 84% (16 false positives), an eightfold increase in errors. These examples illustrate how dramatically ParsSNP reduces errors in comparison to other methods under typical conditions. Figure 4 Comparison of candidate driver mutations in an independent data set identifies known and likely drivers that are only identified by ParsSNP. ParsSNP, CanDrA, and CHASM were applied to the data set from Kakiuchi et al., which consists of 2,988 protein-altering somatic mutations from 30 patients with diffuse-type gastric carcinoma. For each tool, the top 30 predicted drivers were extracted. The candidate drivers themselves are listed according to the tools by which they were identified. DRV, driver identified in original study; CGC, mutation in CGC member; TRN, truncation in known TSG; MUS, mutation in very large muscle protein. 17 . We also applied CanDrA and CHASM, the most recently published and the most cited of the independent tools, respectively. We compared the candidate drivers identified by each tool, defining candidates as the top 1% of ranked mutations (30 mutations per tool). Approximately one-third (11/30) of ParsSNP's candidate drivers were also identified by other methods (Fig. 4) . These candidates included missense mutations in well-established cancer-related genes, including PIK3CA, FGFR2, and TP53 (encoding p53). Two-thirds of ParsSNP's candidate drivers (19/30) were not identified by other tools. These mutations included truncations in known TSGs (ARID1A, CDKN2A, SMAD4, and TP53) 9, 24 , recurrent mutations (CDC27 p.Tyr173Ser), and confirmed drivers (RHOA p.Tyr42Cys) 17 . By comparison, the mutations uniquely identified by CanDrA included biologically implausible drivers in TTN and DMD (encoding the very large skeletal muscle proteins titin and dystrophin) 25 and experimentally confirmed neutral mutations (ERBB2 p.Arg678Gln) 26 . The mutations uniquely identified by CHASM were frequently in genes with no known connection to cancer, as illustrated by the fact that only 2 of 27 were CGC members 19 . Therefore, ParsSNP identifies many likely drivers that other tools do not detect; furthermore, mutations identified exclusively by other tools are often implausible as drivers.
We also explored the data set from Kakiuchi et al. on a per-patient basis, as functional impact scores will frequently be used in this fashion as it becomes common to exome sequence clinical cases. We focused on patients 313T, 319T, and 361T, who had many predicted drivers in well-known cancer-related genes. Table 2 shows the top five candidate drivers identified by ParsSNP, CanDrA, and CHASM in each patient. In patient 313T, ParsSNP correctly identified RHOA p.Tyr42Cys and also suggested PIK3CA p.His1047Leu (p.His1047Arg is a confirmed driver 27 ) and a truncation in the tumor suppressor ARID1A. Of these three plausible drivers, CanDrA and CHASM only identified the PIK3CA mutation. In patient 319T, ParsSNP identified several truncations in the known tumor suppressors SMAD4, ARID1A, and TP53, which the other tools missed because they do not apply to truncations. ParsSNP also informatively suggested that these truncations were more likely to be drivers than the p.Arg56Cys substitution in the cancer-related gene BAP1 (ref. 19 ). In patient 361T, ParsSNP identified missense mutations in the known cancer-related genes TP53, FGFR2, and NOTCH2, as well as a truncation in the tumor suppressor CDKN2A 19 . Of these, CanDrA and CHASM only identified the TP53 and FGFR2 mutations. However, they also identified an implausible candidate driver in DMD (encoding dystrophin; p.Arg137Gln) 25 . We conclude that ParsSNP identifies candidate drivers that are more biologically plausible than those produced by competing methods, both across whole data sets and within individual patients.
Identifying new drivers with ParsSNP
Another use of ParsSNP is to identify biological hypotheses. We pooled ParsSNP scores for the hypermutator, training, and test sets. To narrow the focus, we considered only the 75 unique mutations with ParsSNP scores over 0.5 (Supplementary Table 4) . These mutations included recurrent driver mutations in BRAF (p.Val600Glu), IDH1 (p.Arg132Cys and p.Arg132Leu), and NRAS (p.Gln61Arg), but 54 of 75 mutations were not recurrent, including the top 3: CTNNB1 p.Pro687Leu (ParsSNP = 0.795), NRAS p.Glu153Ala (0.789), and CTNNB1 p.Phe777Ser (0.787). Most of the mutations were within CGC members, but 13 were not: 2 were in TBP (encoding TATA-binding protein; p.Ala191Thr and p.Arg168Gln) and 3 were in KCNN3 (encoding a calcium-dependent potassium channel; p.Arg435Cys, p.Leu413Gln, and p.Ser517Tyr). Moreover, TBP and KCNN3 had generally elevated ParsSNP scores by one-sample Wilcoxon test (Bonferroni P < 0.05; Supplementary Fig. 9 and Supplementary Table 5 ). Taking these results together, ParsSNP suggests these genes as putative cancerrelated genes, with TBP p.Ala191Thr and p.Arg168Gln and KCNN3 p.Arg435Cys, p.Leu413Gln, and p.Ser517Tyr as the most promising driver mutations.
We also examined the differences in ParsSNP scores between hypermutators and non-hypermutators (training and test sets). Whereas many genes had elevated scores exclusively in the non-hypermutators, none could be detected in only the hypermutators ( Supplementary  Fig. 10a ). However, differential functionality analysis on a per-gene basis (Supplementary Fig. 10b ) highlighted two genes-RNF43 (a ubiquitin ligase 28 ) and UPF3A (involved in nonsense-mediated mRNA decay 29 )-that had modestly but significantly elevated 
For patients 313T, 319T, and 361T from the study by Kakiuchi et al., the top five predicted drivers are shown as determined by ParsSNP, CanDrA, and CHASM. DRV, driver identified in original study; CGC, mutation in CGC member; TRN, truncation in known TSG; MUS, mutation in very large muscle protein.
t e c h n i c a l r e p o r t s
ParsSNP scores in the hypermutated samples, suggesting that they might have a role in hypermutator biology.
DISCUSSION
It is likely that only a small fraction of mutations identified by cancer genome sequencing are drivers 2, 11 , making it difficult to direct experimental and clinical decision-making. Functional impact scores can filter out passengers, but shortcomings include limited generalizability due to biases from prelabeled training data. ParsSNP avoids the use of prelabeled training data by using parsimony to generate its own labels. This requires that putative drivers be (i) relatively equitably distributed among samples, which is the basis of the expectation step, and (ii) definable in terms of the descriptors, which is enforced by the maximization step. Using these constraints, we found a single set of labels in the training pan-cancer set and trained a model to generate ParsSNP scores. The assessment of ParsSNP required careful design. A central motivation for this study is the lack of a gold standard for defining drivers and passengers, which would ordinarily be used for both training and assessing a model. While we use parsimony to train ParsSNP, we rely on a series of 'silver standards' for assessment, a strategy proposed by Gonzalez-Perez et al. 21 .
We recognize that these tasks have some weaknesses. For example, in the CGC task, we defined cancer-related genes using the CGC, which may be incomplete or biased by manual curation; an automated definition may be equally valid. Tasks relying on experimental data are similarly biased by the choice of model systems and outcome measures. However, the tasks we selected are diverse, with multiple data sources and types, and it is unlikely that the tasks are systematically biased as a whole.
ParsSNP outperformed existing methods in 24 of 25 comparisons across the five classification tasks. Notably, no single tool can act as an alternative to ParsSNP across all tasks. That ParsSNP performs very well in all tasks is an extremely important finding, as it suggests that ParsSNP's performance relative to that of other tools will be consistent in novel data sets. Although none of these assessments are a gold standard of drivers and passengers, they do resemble data sets that users may assess with ParsSNP and other tools.
To illustrate a typical usage case, we applied ParsSNP to mutations from 30 diffuse-type gastric cancer genomes and found that it identified known and likely candidate drivers that other methods did not detect. In particular, ParsSNP identified truncation events in tumor suppressors. While methods like CanDrA and CHASM are not designed to work with truncation events, it is clear that they are plausible drivers, and the ability to identify and rank them against missense mutations will be an important feature for users. On the basis of our results as a whole, we conclude that ParsSNP is superior to existing methods for quickly identifying likely cancer drivers in somatic cancer mutation data.
Many avenues can be explored to improve ParsSNP performance and broaden its applications. Expanding the set of descriptors is one promising possibility: whereas ParsSNP uses 23 descriptors, CHASM had access to 49 (ref. 7) and CanDrA had 95 (ref. 6) . By expanding and modifying the descriptors, the ParsSNP approach can be adapted beyond protein-altering somatic mutations in cancer. For instance, none of the assumptions that underpin ParsSNP are specific to cancer. With some modifications to the descriptors, one can envision a version of ParsSNP that is trained using germline mutations from patients with other polygenic diseases.
More generally, ParsSNP can be applied to problems that lack sufficient training examples for supervised methods. For example, as more patients are whole-genome sequenced, methods to identify nonprotein-altering drivers of cancer are needed 30 . ParsSNP could be well suited to this task, as there are few validated non-protein-altering cancer drivers. ParsSNP's current descriptors are largely applicable only to protein-altering mutations, but frameworks for defining informative descriptors for non-protein-altering variants already exist 4, 31 . It seems plausible that combining descriptors from these studies with ParsSNP's training approach could produce models that effectively identify protein-altering and non-protein-altering drivers.
The identification of pathogenic mutations can guide experimental and clinical decisions. We believe that ParsSNP can aid in this task by leveraging the configuration of mutations within samples to generate more biologically relevant predictions. We demonstrated the strength and generalizability of ParsSNP when detecting driver mutations in cancer using a variety of data sets; moreover, beyond the direct applications we have demonstrated, ParsSNP represents a novel paradigm for the problem of functional impact prediction that can be extended into a wider variety of data types than is currently possible. 
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Data sets.
A full description of the pan-cancer data set can be found in our previous study 9 . Briefly, mutation data were drawn from TCGA, ICGC, and COSMIC. Data were updated to build hg19, and duplicate data were deleted 32 . Mutations were annotated with ANNOVAR using RefSeq gene and ljb26 libraries 33 . The data set contains 1,703,709 mutations drawn from 10,239 tumors representing 28 cancer types.
We removed potentially biologically distinct hypermutated samples 25, 34 . Because there is no universal cutoff for defining hypermutation 18, 34 , we used the median mutation burden (715 mutations) to generate two equally sized segments that differ only by mutation rate: 435 samples with 851,996 mutations and 9,804 samples with 851,713 mutations. The 9,804 non-hypermutated tumors were randomly split 2:1 to generate a 6,536-tumor (566,223-mutation) training data set and a 3,268-tumor (285,490-mutation) test data set.
We also used external data. We drew 2,314 mutations from the IARC R17 systematic p53 yeast screen collection for benchmarking 15 . Like Reva et al., we averaged the normalized scores of all eight downstream targets to reduce technical variation 35 . We also constructed the driver-dbSNP benchmarking data set from several sources: 289 known activating kinase mutations from Kin-Driver 13 ; 849 known non-neutral mutations from Martelotto et al. 14 , and 49,880 common missense SNPs (minor allele frequency > 1% in human populations) from dbSNP build 142 as presumably non-functional germline mutations. Protein-altering common dbSNP variants were gathered from the UCSC Genome Browser on 14 January 2015, producing 49,880 missense mutations after reannotation. We also made use of 71 experimentally characterized mutations from Kim et al. as the functional-neutral data set 16 . Finally, we drew exome sequencing results from the study by Kakiuchi et al. of 30 diffusetype gastric carcinomas 17 . Once intergenic and intronic mutations were removed, 2,988 mutations remained in this data set. All external data were reannotated and treated the same as our pan-cancer data sets except where noted. Mutations that could not be annotated were excluded.
We also made use of the CGC, a curated list of cancer-related genes 19 . As was done previously, we eliminated genes that had only been associated with translocation events, as many of these genes may not be directly associated with cancer 18 . Similarly, we removed genes that had no recorded somatic mutations according to CGC annotations, leaving 208 cancer-related genes. When we refer to the CGC in the study, we are referring to this reduced set. We further divided this set into putative oncogenes or tumor suppressors on the basis of their annotated genetic profile (dominant or recessive, respectively) 18 . Genes with ambiguous profiles were excluded.
Mutation-level descriptors. ParsSNP uses 19 mutation-level descriptors.
Rather than directly train on functional, structural, or evolutionary descriptors, ParsSNP incorporates such data indirectly by including 16 previous functional impact scores from the ANNOVAR ljb26 libraries 33 . They include established tools such as SIFT, PolyPhen-2, MutationAssessor, FATHMM, VEST, CADD, and others (Supplementary Table 3) . We add three additional mutation-level descriptors. Normalized Position is equal to mutation position divided by protein length. The Blossum62 score was assigned for amino acid substitutions. The final descriptor is mutation type, which is encoded as two variables (VarClassS and VarClassT) that indicate if the mutation is silent (including synonymous, intronic, and untranslated mutations) or truncating (including frameshift, splice-site, non-stop, and nonsense mutations).
Gene-level descriptors. Four descriptors provide gene-level data. The first is protein length. The rest are drawn from our previous study 9 . 'Unaffected residues' for the presence of nonrandom mutation recurrence within the gene. 'Truncation rate' tests for enrichment or depletion of truncation events within a gene. Finally, 'cancer type distribution' tests for genes that are mutated in nonrandom subsets of cancers. We chose these three tests because they are non-redundant with the other information sources available to ParsSNP. These tests were calculated as outlined previously using the training data set and applied to additional data sets as annotations.
Imputation and data scaling. Because ParsSNP relies on all mutations within a tumor, we cannot remove mutations with missing data without removing whole samples (which would quickly deplete the data set). Therefore, we make use of data imputation at several levels.
Most important is the handling of non-missense mutations, to which many functional impact scores do not apply. We adapted the strategy of OncodriveFM to impute these values 36 . We consider truncations (nonsense, non-stop, splice-site, and frameshift and in-frame indels) as more likely to be drivers, whereas we consider silent mutations (synonymous, intronic, and untranslated) as less likely to be drivers. For 9 of 16 functional impact scores, a classification as functional or neutral is made on the basis of thresholds provided by the original authors 33 . Truncation events with missing values were assigned the average value given to predicted functional mutations. Similarly, silent mutations with missing values were assigned the average value of neutral missense mutations. For tools that had them, intermediate classes were deemed functional. For scores without classification thresholds, we used the 95th and 5th percentiles as imputation values for the truncation and silent mutation classes, respectively. ParsSNP results are robust to reasonable changes in the percentiles used.
Remaining missing values are then replaced by mean imputation. Only one of the descriptors had more than 5% missingness in the training set, and none were greater than 10%. Finally, the training set is scaled so that each descriptor is in the range [0,1], in keeping with best practice for neural network models 37 . Wherever applicable, descriptors, imputation and scaling values were calculated using the training set and applied to other data sets.
Adapting the expectation-maximization algorithm. The expectationmaximization algorithm can fit statistical models with missing or latent data 38 . However, it requires that constraints be placed on the possible solutions. For instance, Zaretzki et al. used the expectation-maximization algorithm to predict atomic sites of P450 metabolism using region-level data but constrained the number of metabolic sites per region 12 . In ParsSNP's learning phase, the missing data are the status of mutations as drivers or passengers, which is constrained so that (i) drivers are relatively equitably distributed among samples (expectation step) and (ii) they are consistent with the descriptors (maximization step).
Learning initialization. ParsSNP begins with descriptors for an unlabeled training set of mutations (X matrix), with each mutation belonging to a biological sample. ParsSNP uses expectation-maximization to find labels for the training mutations; more precisely, as a probabilistic model, ParsSNP finds probabilities that describe the unseen, binary driver/passenger labels. We initialize ParsSNP with a random uniform vector of probabilities. Samples are assigned to equally sized folds that will be used during the maximization step throughout the training process, such that mutations never inform their own updates.
The expectation step. The expectation step updates probabilities on the basis of the combination of mutations within samples. The probabilities for a given sample (Y) are updated under the belief that the unseen total number of driver mutations in the sample (t) is between a lower (l) and upper (u) bound. Each probability is updated on the basis of the following question: of all the possible configurations of driver/passenger binary labels for the sample in which t is between l and u, what proportion require the mutation be a driver (weighted by probability)?
This can be formalized using Bayes' law and some additional definitions. M is the unseen vector of binary mutation labels that sum to t in each sample, while m is the unseen label of the given mutation. Y is the current vector of probabilities, while y is the probability of the given mutation. We denote values that exclude the mutation using prime notation. Given these definitions, the value of y can be updated with the following equation
Although we cannot calculate t and t′ directly, our beliefs regarding the mutation labels M and M′ are described by Y and Y′. Therefore, t and t′ can be treated as Poisson binomial random variables parameterized by Y and Y′ (ref. 39 ). For each sample in the data set, Bayes' law is applied to each mutation. The Poisson binomial cumulative density function is calculated exactly in samples with fewer than 30 mutations and with a refined normal approximation for samples with more mutations 39 .
The most important parameters in the expectation step are the lower and upper bounds. The lower bound is the simpler of the two and is fixed at one driver per sample. A higher value lacks biological justification in cancer, as tumors have been observed with no exomic mutations 40 . However, setting the lower bound to zero leads the algorithm to converge on a vector of zeroes; this is consistent with the constraint but non-informative ( Supplementary Fig. 2  and Supplementary Table 2) .
The upper bound is more complex as the algorithm makes use of two versions. The 'fixed' upper bound is defined as log 2 (mutation burden). Therefore, a sample with 8 mutations is believed to have between 1 and 3 drivers, whereas a sample with 1,024 mutations is believed to have between 1 and 10 drivers; these ranges illustrate how drivers are presumed to be more equitably distributed than passengers. Using log 2 as a function yields reasonable upper bounds over the range of mutation burdens; however, its stringency can cause underflow errors even with double precision arithmetic. The problem most often occurs in very highly mutated samples in early iterations. Therefore, we define a second, less stringent 'sliding' upper bound that is often used initially and is set to some proportion (p) of the total current belief for the sample (default p = 0.9). The expectation step uses whichever is greater of the sliding and fixed upper bounds. For instance, a sample with 1,024 mutations is initialized with a random vector of probabilities and is therefore currently expected to have ~500 functional mutations on average. The sliding upper bound is p × 500 = 450, whereas the fixed upper bound is log 2 (1,024) = 10. Given the current probabilities, the probability of the total number of drivers being less than ten is essentially zero, requiring the use of the sliding upper bound. The sliding upper bound applies a consistent, downward pressure on probabilities until the fixed upper bound can be used without risking underflow errors. The algorithm is robust to reasonable alternatives for defining both upper bounds ( Supplementary Fig. 2 and Supplementary Table 2 ).
These concepts are clearer when viewing the expectation step code (see URLs). An important point should be made here however: the upper and lower bounds are 'soft' bounds. In the final solution, many samples will be assigned a number of drivers beyond the suggested bounds. Although these bounds are important to understanding the behavior of the expectation step, in practice, any reasonable function for defining these values leads to similar results. The maximization step. Samples are assigned to one of five cross-validation folds, which are fixed so that samples never inform their own updates. ParsSNP was robust to changes in the number of folds ( Supplementary  Fig. 2 and Supplementary Table 2 ). We fit a single-layer neural network to the data, which is capable of producing well-scaled outputs that can be interpreted as probabilities by the expectation step 12 . The neural network parameters are set by grid search (weight decay (0.1, 0.01, 0.001), size (6, 12, 18) ) through bootstrap selection (10 samples of 10,000 mutations each). The cross-validated predicted probabilities are then returned and passed to the expectation step if the stop criteria are not satisfied. Algorithm stop and model training. The algorithm ends once the vector of probabilities stabilizes, defined as a mean-square difference (MSD) of less than 1 × 10 −5 between iterations or a change in MSD of less than 5% between iterations. In practice, the second relative cutoff was invoked more often, but the algorithm consistently converged by 30 iterations even under highly stringent cutoffs.
The final result is a vector of probabilities for the training data that optimally meets our constraints and are interpreted by ParsSNP as the probability of each mutation acting as a driver. These probabilities are referred to as 'ParsSNP labels' . As cross-validation is non-deterministic, we average the results of 50 runs of the algorithm to generate a final result (ParsLR was trained with 50 runs, ParsFIS and ParsNGene were trained with 10 runs, and cancer-specific models were trained with 5 runs; see below for descriptions). The final ParsSNP neural network is trained with the labels and descriptors using identical settings as the maximization step, although other model types or descriptors could be used at this stage. The final model is then applied to the various data sets to produce ParsSNP scores.
Methodological controls. We applied several methodological controls to the classification tasks to help understand ParsSNP's performance ( Supplementary  Figs. 3-7 and Supplementary Table 3) . We include several simplified variations of ParsSNP for comparison. ParsLR uses logistic regression rather than a neural network. ParsFIS uses only the 16 descriptor functional impact scores, whereas ParsNGene excludes the 3 gene-level descriptors ('truncation rate' , 'unaffected residues' , 'cancer type distribution') 9 . For the classification tasks with sufficient data, we also include supervised versions of ParsSNP, which use neural networks and all descriptors but are trained to perform each task directly. The recurrence-trained and CGC-trained models are trained in the pan-cancer training set and assessed in the test set. The models trained with driver-dbSNP and p53 were trained and tested using tenfold cross-validation directly in the corresponding data sets, as we had insufficient data for separate training and test sets in these cases. The model type, and tuning procedure, and the labels are identical to those used during ParsSNP's training and assessment. Because ParsSNP incorporates several gene-level descriptors, we ran genelevel tools that are designed to detect cancer-related genes on the pan-cancer training set and then assessed their performance in the test set (MutSigCV, OncodriveFM, and OncodriveCLUST 25, 36, 41 ). We also consider CGC membership as a simple approach for defining drivers. Methods that required tuning or training (like the gene-level tools and supervised versions) were trained once on the relevant training data and were not retrained between classification tasks.
Using logistic regression (ParsLR) rather than a neural network slightly degraded ParsSNP's performance in most tasks. Gene-level tools (OncodriveFM, OncodriveCLUST, and MutSigCV) generally do not perform well in the tasks when used in isolation; however, removing the gene-level descriptors from ParsSNP does markedly degrade performance in most tasks (ParsFIS and ParsNGene). The only exception was OncodriveCLUST, which performed well in the recurrence task (AUROC = 0.72); this is not surprising, since it is specifically designed to detect genes with many clustered and recurrent mutations, and should perform well in this particular task. Supervised learning is not as effective as the unsupervised EM training in 15 of 20 comparisons. As expected, supervised models often performed well at the tasks they were trained to perform, but unlike ParsSNP their performance was inconsistent in other tasks. We conclude that the most important source of ParsSNP's performance is the combination of the novel feature set (particularly the inclusion of gene-level features) with the unsupervised EM training.
Model Improvement. Two approaches for improving ParsSNP are to add additional data or focus the model on particular cancer types. Testing ParsSNP on subsets of the training data shows that performance does not degrade until the data set drops to less than ~250-500 samples (~5-10% of the training data; Supplementary Fig. 11 ). This suggests that merely adding data will not improve the model.
We next considered narrowing the scope to a single cancer type. Versions of ParsSNP were trained and tested in breast cancer, lung adenocarcinoma, melanoma, colorectal adenocarcinoma, or head and neck squamous cell carcinoma (cancers with 150+ patients and 25,000+ mutations in the training set; Supplementary Table 6 ). The pan-cancer version of ParsSNP generally outperformed these more targeted models. However, predictions made by cancer-specific and pan-cancer ParsSNP models were not very correlated, and aggregate performance may mask important differences. Additional data for these cancer types will clarify whether these results are a consequence of noise or true biological differences.
We also explored the use of thresholding. Because ParsSNP is trained using unlabeled mutations, there is no single objective criterion for setting a ParsSNP threshold. One option is to optimize the percentage of samples assigned a number of drivers meeting the expectation step boundaries. This approach suggests a threshold of 0.07 for non-hypermutators and 0.12 for hypermutators (Supplementary Fig. 12a ). Alternatively, a threshold could be selected to optimize accuracy in the classification tasks, suggesting a range of 0.08 to 0.16 ( Supplementary Fig. 12b and Supplementary Table 7) . Although a ParsSNP cutoff of 0.1 may be reasonable in many situations, the observed variations suggest that thresholds be set in a context-specific manner, taking into account the relative importance of sensitivity and specificity for the task at hand.
